Arcadia Biosciences Activates Resale of 11.9M Shares, Potential 546% Dilution

summarizeSummary

Arcadia Biosciences has activated the resale of 11.9 million shares by selling stockholders, originating from a recent private placement, which could lead to over 500% dilution for current shareholders.

check_boxKey Events · Financing and Capital Events · RKDA

• Resale of 11.9 Million Shares Activated

  The company filed a prospectus supplement to register the resale of up to 11,922,333 shares of common stock by selling stockholders, making these shares available for sale in the market.

• Massive Potential Dilution

  The 11.9 million shares represent a potential dilution of approximately 546% compared to the 2,181,715 shares outstanding before this offering, creating significant overhang.

• Shares from Recent Private Placement

  These shares are issuable upon the exercise of pre-funded warrants and preferred investment options issued in a $4 million private placement completed on June 12, 2026.

• No Direct Proceeds from Resale

  Arcadia Biosciences will not receive any proceeds from the sale of shares by the selling stockholders; however, it could receive up to $7.4 million if all underlying options are exercised for cash.

auto_awesomeAnalysis · RKDA · Energy & Transportation

This filing activates the resale of 11.9 million shares by selling stockholders, primarily Armistice Capital, which were issued in a recent private placement. This represents a potential dilution of over 500% to existing shareholders, creating significant selling pressure on the stock. While the company could receive up to $7.4 million if all underlying options are exercised for cash, it will not receive any proceeds from the actual resale of these shares. This event is critical given the company's severe financial distress, including a reiterated going concern warning and a $4.0 million debt default reported in its last 10-Q.